Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 04 Jan 2018 Planned primary completion date changed from 1 Mar 2020 to 27 Jan 2017.
- 04 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Dec 2016 Planned initiation date changed from 1 Nov 2016 to 1 Jan 2017.